


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

**VOLUNTARY ANNOUNCEMENT
“MIRABEGRON SUSTAINED-RELEASE TABLETS”
OBTAINED DRUG REGISTRATION CERTIFICATE**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, “Mirabegron Sustained-release Tablets” (trade name: Gu Zheng (固正)), a drug developed by the Group for urinary system, has been granted the drug registration certificate by the National Medical Products Administration of China. The product was filed as a drug under Chemicals Category 4, and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs, being the second generic drug of its kind that has obtained approval for drug registration in China.

Mirabegron is a selective beta-adrenergic receptor agonist for the auxiliary treatment of urgent urination, frequent urination and/or urge incontinence in adults with overactive bladder (OAB). By acting on the beta-adrenergic receptors, Mirabegron selectively relaxes the detrusor muscle of bladder and facilitates urine storage, thereby increasing bladder capacity and lengthening the voiding interval without affecting bladder emptying.

Mirabegron has been included in the “List of Second Batch of Encouraged Generic Drugs” issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration and was admitted to the national medical insurance in 2020 in China. The approval of Mirabegron Sustained-release Tablets of the Group provides a new medication option for patients with overactive bladder in China.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 17 March 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.